Literature DB >> 33550359

[Clinical analysis of 61 patients with thrombotic thrombocytopenic purpura].

M J Shi1, W B Gao2, W F Huang2, J H Zhu2.   

Abstract

OBJECTIVE: To analyze and summarize the clinical features, diagnosis, treatment and prognosis of 61 patients with thrombotic thrombocytopenic purpura (TTP), so as to improve the ability of diagnosis and treatment.
METHODS: The clinical data of 61 TTP patients admitted to Peking University People's Hospital from January 2004 to March 2019 were retrospectively analyzed, and the clinical manifestations, blood routine, hemolysis indicators, and von Willebrand factor lyase (von Willebrand factor-cleaving protease, vWF-CP, also known as ADAMTS13) of these patients were observed. According to the outcome at the time of discharge, they were divided into survival group and death group, and the differences in clinical characteristics, neutrophil to lymphocyte ratio (NLR) and plasma exchange between the two groups were compared. The PLASMIC scores were calculated and compared with ADAMTS13 to determine the accuracy of the PLASMIC score in predicting ADAMTS13.
RESULTS: Among the 61 TTP patients, 22 were males and 39 were females, with an average age of (48±17) years. In the study, 48 cases had pentalogy, only 9 had triad, and the remaining 4 had no neuropsychiatric symptoms. Twenty-seven cases (44.3%) died and 34 cases (55.7%) survived. Among the 61 TTP patients, the platelet count was (12.9±9.5)×109/L, the hemoglobin (66.5±20.7) g/L, the percentage of erythrocyte fragments 3% (2%, 7%), and the plasma free hemoglobin increased to 360 (200, 457) mg /L, and the lactate dehydrogenase 1 508 (811, 2 133.8) U/L. The blood clotting was basically normal. The ADAMTS13 value of 30 patients was 49.0 (40.8, 61.3) μg/L, the ADAMTS activity of 10 patients was < 5%, and the remaining 21 patients were not checked. The PLASMIC score was 6-7 in 58 cases, 5 in 2 cases, and 4 in 1 case. The PLASMIC score predicted the decreased activity or the reduction of ADAMTS with a sensitivity as high as 97.5%. The NLR in the death group was higher than that in the survival group, but the difference was not statistically significant (P>0.05). The total amount and frequency of plasma exchange (PEX) in the death group were significantly less than those in the survival group, and the difference was statistically significant (P < 0.05). There was no significant difference in the treatment of glucocorticoids and human immunoglobulin between the two groups (P>0.05).
CONCLUSION: PEX can significantly improve the survival rate of TTP patients. PLASMIC score can easily and quickly predict the possibility of ADAMTS13 activity reduction, which is beneficial to the early diagnosis of TTP and PEX treatment. NLR can reflect the systemic inflammatory process, but its significance in TTP needs further study.

Entities:  

Keywords:  Plasma exchange; Thrombotic thrombocytopenic purpura; Von willebrand factor-cleaving protease

Mesh:

Substances:

Year:  2020        PMID: 33550359      PMCID: PMC7867995     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  16 in total

Review 1.  Thrombosis, Microangiopathies, and Inflammation.

Authors:  Karen Matevosyan; Ravi Sarode
Journal:  Semin Thromb Hemost       Date:  2015-08-15       Impact factor: 4.180

2.  [Consensus of Chinese experts on diagnosis and treatment of thrombotic thrombocytopenic purpura (version 2012)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2012-11

3.  Adjuvant rituximab to prevent TTP relapse.

Authors:  Adam Cuker
Journal:  Blood       Date:  2016-06-16       Impact factor: 22.113

4.  Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Authors:  Miguel Hie; Julie Gay; Lionel Galicier; François Provôt; Claire Presne; Pascale Poullin; Guy Bonmarchand; Alain Wynckel; Ygal Benhamou; Philippe Vanhille; Aude Servais; Dominique Bordessoule; Jean-Philippe Coindre; Mohamed Hamidou; Jean-Paul Vernant; Agnès Veyradier; Paul Coppo
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

5.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.

Authors:  Maria Piedad Ruiz-Torres; Federica Casiraghi; Miriam Galbusera; Daniela Macconi; Sara Gastoldi; Marta Todeschini; Francesca Porrati; Daniela Belotti; Enrico Maria Pogliani; Marina Noris; Giuseppe Remuzzi
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

7.  Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.

Authors:  Pavan K Bendapudi; Shelley Hurwitz; Ashley Fry; Marisa B Marques; Stephen W Waldo; Ang Li; Lova Sun; Vivek Upadhyay; Ayad Hamdan; Andrew M Brunner; John M Gansner; Srinivas Viswanathan; Richard M Kaufman; Lynne Uhl; Christopher P Stowell; Walter H Dzik; Robert S Makar
Journal:  Lancet Haematol       Date:  2017-03-02       Impact factor: 18.959

8.  Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura.

Authors:  Bálint Mikes; György Sinkovits; Péter Farkas; Dorottya Csuka; Agota Schlammadinger; Katalin Rázsó; Judit Demeter; Gyula Domján; Marienn Réti; Zoltán Prohászka
Journal:  Thromb Res       Date:  2014-02-01       Impact factor: 3.944

Review 9.  Neutrophil extracellular traps (NETs) - formation and implications.

Authors:  Marcin Zawrotniak; Maria Rapala-Kozik
Journal:  Acta Biochim Pol       Date:  2013-07-01       Impact factor: 2.149

10.  Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.

Authors:  Marie Scully; Beverley J Hunt; Sylvia Benjamin; Ri Liesner; Peter Rose; Flora Peyvandi; Betty Cheung; Samuel J Machin
Journal:  Br J Haematol       Date:  2012-05-25       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.